Sandoz to invest $1 billion in European biosimilar hub, targeting 100 biosimilars by 2040

Sandoz announced at its investor day that it will spend roughly $1 billion to build a fully integrated European biosimilar hub as part of a plan to bring more than 100 biosimilars to market by 2040.

The company is allocating $300 million to a new drug substance facility in Ljubljana, Slovenia, which will feature an 8,000‑liter disposable fed‑batch capacity for low‑ to medium‑volume biologic production.

Higher‑volume products will be manufactured at a separate site in Lendava, Slovenia, where a stainless‑steel drug substance center is slated for completion this year, and a $440 million sterile product plant in Brnik is expected to open in 2028.

Together, these sites form a vertically integrated supply chain designed to accelerate Sandoz’s biosimilar portfolio growth across Europe.